This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, ...
The new approval allows for the 2000mg loading dose to be administered as an IV push rather than a 30-minute IV infusion. The prescribing information for Trogarzo ® (ibalizumab-uiyk) has been updated ...
Safety profile of Trogarzo ® IV push similar to that of IV infusion New method of administration designed to make maintenance dosing easier for patients and health care providers and allow more ...
The approval was based on data from the phase 3 TMB-302 trial that evaluated Trogarzo 800mg administered via IV push once every 2 weeks. The Food and Drug Administration (FDA) has approved Trogarzo ® ...
The U.S. Food and Drug Administration has expanded the approval of Cinvanti injectable emulsion to include a two-minute intravenous use for the prevention of acute and delayed chemotherapy-induced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback